241 related articles for article (PubMed ID: 22156223)
21. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.
Lo SC; Li X; Henzl MT; Beamer LJ; Hannink M
EMBO J; 2006 Aug; 25(15):3605-17. PubMed ID: 16888629
[TBL] [Abstract][Full Text] [Related]
22. Recapitulating the Binding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided by NMR, X-ray Crystallography, and Machine Learning.
Ortet PC; Muellers SN; Viarengo-Baker LA; Streu K; Szymczyna BR; Beeler AB; Allen KN; Whitty A
J Am Chem Soc; 2021 Mar; 143(10):3779-3793. PubMed ID: 33683866
[TBL] [Abstract][Full Text] [Related]
23. Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1.
Eggler AL; Small E; Hannink M; Mesecar AD
Biochem J; 2009 Jul; 422(1):171-80. PubMed ID: 19489739
[TBL] [Abstract][Full Text] [Related]
24. Characterization of RA839, a Noncovalent Small Molecule Binder to Keap1 and Selective Activator of Nrf2 Signaling.
Winkel AF; Engel CK; Margerie D; Kannt A; Szillat H; Glombik H; Kallus C; Ruf S; Güssregen S; Riedel J; Herling AW; von Knethen A; Weigert A; Brüne B; Schmoll D
J Biol Chem; 2015 Nov; 290(47):28446-28455. PubMed ID: 26459563
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction.
Hu L; Magesh S; Chen L; Wang L; Lewis TA; Chen Y; Khodier C; Inoyama D; Beamer LJ; Emge TJ; Shen J; Kerrigan JE; Kong AN; Dandapani S; Palmer M; Schreiber SL; Munoz B
Bioorg Med Chem Lett; 2013 May; 23(10):3039-43. PubMed ID: 23562243
[TBL] [Abstract][Full Text] [Related]
26. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents.
Abed DA; Goldstein M; Albanyan H; Jin H; Hu L
Acta Pharm Sin B; 2015 Jul; 5(4):285-99. PubMed ID: 26579458
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
[TBL] [Abstract][Full Text] [Related]
28. Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides.
Karttunen M; Choy WY; Cino EA
J Phys Chem B; 2018 Jun; 122(22):5851-5859. PubMed ID: 29745220
[TBL] [Abstract][Full Text] [Related]
29. A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
Tran KT; Pallesen JS; Solbak SMØ; Narayanan D; Baig A; Zang J; Aguayo-Orozco A; Carmona RMC; Garcia AD; Bach A
J Med Chem; 2019 Sep; 62(17):8028-8052. PubMed ID: 31411465
[TBL] [Abstract][Full Text] [Related]
30. Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2).
Zhong M; Lynch A; Muellers SN; Jehle S; Luo L; Hall DR; Iwase R; Carolan JP; Egbert M; Wakefield A; Streu K; Harvey CM; Ortet PC; Kozakov D; Vajda S; Allen KN; Whitty A
Biochemistry; 2020 Feb; 59(4):563-581. PubMed ID: 31851823
[TBL] [Abstract][Full Text] [Related]
31. Structural basis of Keap1 interactions with Nrf2.
Canning P; Sorrell FJ; Bullock AN
Free Radic Biol Med; 2015 Nov; 88(Pt B):101-107. PubMed ID: 26057936
[TBL] [Abstract][Full Text] [Related]
32. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.
Hayes JD; McMahon M
Trends Biochem Sci; 2009 Apr; 34(4):176-88. PubMed ID: 19321346
[TBL] [Abstract][Full Text] [Related]
33. Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
Khan H; Killoran RC; Brickenden A; Fan J; Yang D; Choy WY
Biochem J; 2015 Apr; 467(1):141-51. PubMed ID: 25582950
[TBL] [Abstract][Full Text] [Related]
34. Measuring the Interaction of Transcription Factor Nrf2 with Its Negative Regulator Keap1 in Single Live Cells by an Improved FRET/FLIM Analysis.
Dikovskaya D; Appleton PL; Bento-Pereira C; Dinkova-Kostova AT
Chem Res Toxicol; 2019 Mar; 32(3):500-512. PubMed ID: 30793592
[TBL] [Abstract][Full Text] [Related]
35. Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery.
Narayanan D; Tran KT; Pallesen JS; Solbak SMØ; Qin Y; Mukminova E; Luchini M; Vasilyeva KO; González Chichón D; Goutsiou G; Poulsen C; Haapanen N; Popowicz GM; Sattler M; Olagnier D; Gajhede M; Bach A
J Med Chem; 2022 Nov; 65(21):14481-14526. PubMed ID: 36263945
[TBL] [Abstract][Full Text] [Related]
36. Fuzzy complex formation between the intrinsically disordered prothymosin α and the Kelch domain of Keap1 involved in the oxidative stress response.
Khan H; Cino EA; Brickenden A; Fan J; Yang D; Choy WY
J Mol Biol; 2013 Mar; 425(6):1011-27. PubMed ID: 23318954
[TBL] [Abstract][Full Text] [Related]
37. Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding Mode.
Georgakopoulos N; Talapatra S; Dikovskaya D; Dayalan Naidu S; Higgins M; Gatliff J; Ayhan A; Nikoloudaki R; Schaap M; Valko K; Javid F; Dinkova-Kostova AT; Kozielski F; Wells G
J Med Chem; 2022 May; 65(10):7380-7398. PubMed ID: 35549469
[TBL] [Abstract][Full Text] [Related]
38. New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations.
Cheng L; Wang H; Li S; Liu Z; Wang C
Life Sci; 2021 Oct; 282():119791. PubMed ID: 34229009
[TBL] [Abstract][Full Text] [Related]
39. Molecular and chemical regulation of the Keap1-Nrf2 signaling pathway.
Keum YS; Choi BY
Molecules; 2014 Jul; 19(7):10074-89. PubMed ID: 25014534
[TBL] [Abstract][Full Text] [Related]
40. Activation of the Nrf2/ARE pathway via S-alkylation of cysteine 151 in the chemopreventive agent-sensor Keap1 protein by falcarindiol, a conjugated diacetylene compound.
Ohnuma T; Nakayama S; Anan E; Nishiyama T; Ogura K; Hiratsuka A
Toxicol Appl Pharmacol; 2010 Apr; 244(1):27-36. PubMed ID: 20026152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
